Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Immune-related adverse events (irAEs) are side effects that reflect the activation of patients' immune systems after treatment with immune checkpoint inhibitors (ICIs). However, there is no meta-analysis on the effect of early irAEs on patient survival. Thus, we assessed the association between early irAEs and the survival of patients treated with ICIs.
Methods: PubMed, Embase, and Web of Science were searched from May 2010 to May 2020 for all the retrospective and prospective comparative studies to evaluate the hazard ratios (HRs) for death. A random-effects model was used to calculate the pooled HR for death, and heterogeneity was assessed using I² statistics. The main outcomes were overall survival (OS) and progression-free survival (PFS).
Results: A total of 11 reports with 2077 patients were included. A significant association was observed between early irAEs and a favorable clinical outcome. Patients with early irAEs had prolonged OS (HR: 0.62, 95% confidence interval (CI): 0.53-0.74, < 0.001) and PFS (HR: 0.53, 95% CI: 0.41-0.66, < 0.001) compared to those without; these results were confirmed using a sensitivity analysis. The irAE types, malignancy types, and sample size were correlated with patients' clinical outcomes.
Conclusions: Early irAEs, especially cutaneous irAEs, correlated with a better clinical outcome in patients treated with ICIs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917734 | PMC |
| http://dx.doi.org/10.3390/jcm12030736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis.
J Infect Dev Ctries
August 2025
Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
Introduction: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized.
View Article and Find Full Text PDFEffects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients.
Int J Cancer
September 2025
Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Immune checkpoint inhibitors (ICIs) are effective anti-tumor agents, but new immune-related side effects (irAEs) are emerging. This retrospective cohort study investigated 461 lung cancer patients treated with ICIs over 2 years, analyzing changes in pulmonary artery diameter (PAD), aortic diameter (AoD), and the pulmonary artery/aortic diameter (PAD/AoD) ratio through chest computed tomography (CT) at baseline, 3 months, 6 months, 1 year, and 2 years post-treatment. The PAD increased from 25.
View Article and Find Full Text PDFTiming of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.
Eur J Cancer
August 2025
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan; Department of Immunopathology, Immunology Frontier Research Center, The University of Osaka, Japan; Centerfor Advanced Modalities and DDS, The University of Osaka, Japan; Center
Background: Circadian rhythms modulate immunity, and a preclinical study suggests that the timing of the first immune checkpoint inhibitor dose affects antitumor efficacy. However, clinical confirmation is scarce. We aimed to evaluate whether the timing of the first pembrolizumab infusion affects outcomes in unresectable non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFElectrophysiological findings in immune checkpoint inhibitor-related neuromuscular events.
Clin Neurophysiol
August 2025
Department of Clinical Neurophysiology. Vall d'Hebron University Hospital. Passeig de la Vall d'Hebron, 119 Barcelona, Spain. Electronic address:
Introduction: Immune checkpoint inhibitors (ICIs) have become key therapies for various malignancies by restoring antitumor immunity. However, they may trigger immune-related adverse events (irAEs), including neurological irAEs (n-irAEs), which, though rare, can be severe. Among these, neuromuscular disorders affecting peripheral nerves, the neuromuscular junction (NMJ), and muscle are the most frequent and carry the highest mortality risk, warranting prompt recognition.
View Article and Find Full Text PDFRelapsing polychondritis following PD-1 blockade diagnosed via 18F-FDG PET/CT and improved by steroid administration: a case report and literature review.
Front Immunol
September 2025
Respiratory and Critical Care Department, The First Hospital of China Medical University, Shenyang, China.
Background: Up to 22% of cancer patients treated with immune checkpoint inhibitors (ICIs) can experience immune-related adverse events (irAEs) that mimic rheumatic disease, such as relapsing polychondritis (RP), which is a rare autoimmune disease that mainly manifests as inflammation of airway cartilage.
Methods: We report a case of RP induced by humanized recombinant anti-PD-1 monoclonal antibody therapy (tislelizumab). 18F-Fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) contributed to the diagnosis of RP, and methylprednisolone was used to effectively control its progression.